- CA$1.15bn
- CA$1.06bn
- CA$450.09m
Brief: Knight Therapeutics Expects To File Its Q1 2020 Financial Results On June 26, 2020
Brief: Knight Announces The Re-Launch Of Trelstar® In Canada
Brief: Knight Therapeutics Announces Approval Of Ibsrela™ In Canada
Brief: Knight Therapeutics Inc. Announces Triumvira Loan Repayment
Brief: Knight Therapeutics Reports Q4 Loss Per Share Of $0.049
Brief: Knight Therapeutics Says As Of March 27, COVID-19 Outbreak Had No Material Impact On Co's Results
Canada Research Roundup: Norbord, Spin Master, West Fraser Timber
Brief: Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their Businesses
Onconova Therapeutics soars on licensing agreement after record-low session
Brief: Knight Therapeutics Inc- QTRLY Revenue C$4 Million Versus C$ 3.2 Million
Brief: Knight And TherapeuticsMD Announce Filing Of New Drug Submission For Joyesta In Canada
Canada's Knight Therapeutics to acquire Biotoscana control by Nov 29-filing
Brief: Brazil's Biotoscana Appoints Claudio Coracini As Interim CEO After Agreement To Sell Control To Knight Therapeutics- Filing
Press Digest: Canada- Oct 22
Canada's Knight Therapeutics: Jumps on $281 mln deal to buy Biotoscana
Knight Therapeutics to purchase Biotoscana in $281 mln deal (updated)
Shares in Biotoscana, Knight Therapeutics up after deal announcement
Brief: Knight Therapeutics To Acquire Grupo Biotoscana
Latin American pharma Biotoscana confirms in sale talks - filing